{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T11:32:34Z","timestamp":1773055954383,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002661","name":"Fund for Scientific Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ymgme.2023.107712","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T08:42:37Z","timestamp":1698136957000},"page":"107712","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["DBS are suitable for 1,5-anhydroglucitol monitoring in GSD1b and G6PC3-deficient patients taking SGLT2 inhibitors to treat neutropenia"],"prefix":"10.1016","volume":"140","author":[{"given":"Joseph P.","family":"Dewulf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Chevalier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Marie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Veiga-da-Cunha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ymgme.2023.107712_bb0005","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1086\/302068","article-title":"A gene on chromosome 11q23 coding for a putative glucose- 6-phosphate translocase is mutated in glycogen-storage disease types Ib and Ic","volume":"63","author":"Veiga-da-Cunha","year":"1998","journal-title":"Am. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107712_bb0010","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa0805051","article-title":"A syndrome with congenital neutropenia and mutations in G6PC3","volume":"360","author":"Boztug","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2023.107712_bb0015","series-title":"Inborn Metabolic Diseases","article-title":"The slycogen storage diseases and related disorders","author":"Walter","year":"2022"},{"issue":"2","key":"10.1016\/j.ymgme.2023.107712_bb0020","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1067\/mpd.2000.105232","article-title":"Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: results of the European study on glycogen storage disease type I","volume":"137","author":"Visser","year":"2000","journal-title":"J. Pediatr."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107712_bb0025","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1073\/pnas.1816143116","article-title":"Failure to eliminate a phosphorylated glucose analog leads to neutropenia in patients with G6PT and G6PC3 deficiency","volume":"116","author":"Veiga-da-Cunha","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10","key":"10.1016\/j.ymgme.2023.107712_bb0030","article-title":"Treatment of the neutropenia associated with GSD1b and G6PC3 deficiency with SGLT2 inhibitors","volume":"13","author":"Veiga-da-Cunha","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ymgme.2023.107712_bb0035","first-page":"55","article-title":"1,5-Anhydro-D-glucitol--a novel type of sugar in the human organism","volume":"201","author":"Pitkanen","year":"1990","journal-title":"Scand. J. Clin. Lab. Investig. Suppl."},{"issue":"2 Pt 1","key":"10.1016\/j.ymgme.2023.107712_bb0040","first-page":"E268","article-title":"Origin and disposal of 1,5-anhydroglucitol, a major polyol in the human body","volume":"263","author":"Yamanouchi","year":"1992","journal-title":"Am. J. Phys."},{"issue":"7","key":"10.1016\/j.ymgme.2023.107712_bb0045","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd3180","article-title":"SGLT2 inhibition--a novel strategy for diabetes treatment","volume":"9","author":"Chao","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107712_bb0050","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jchf.2018.11.013","article-title":"Practical guide to prescribing sodium-glucose cotransporter 2 inhibitors for cardiologists","volume":"7","author":"Vardeny","year":"2019","journal-title":"JACC Heart Fail."},{"issue":"16","key":"10.1016\/j.ymgme.2023.107712_bb0055","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107712_bb0060","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ymgme.2023.107712_bb0065","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood.2019004465","article-title":"Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor","volume":"136","author":"Wortmann","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ymgme.2023.107712_bb0070","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/jimd.12509","article-title":"Successful use of empagliflozin to treat neutropenia in two G6PC3-deficient children: impact of a mutation in SGLT5","volume":"45","author":"Boulanger","year":"2022","journal-title":"J. Inherit. Metab. Dis."},{"issue":"8","key":"10.1016\/j.ymgme.2023.107712_bb0075","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.gim.2022.04.001","article-title":"Efficacy and safety of empagliflozin in glycogen storage disease type Ib: data from an international questionnaire","volume":"24","author":"Grunert","year":"2022","journal-title":"Genet. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107712_bb0080","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13023-022-02345-2","article-title":"Understanding the role of SGLT2 inhibitors in glycogen storage disease type Ib: the experience of one UK centre","volume":"17","author":"Halligan","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"issue":"8","key":"10.1016\/j.ymgme.2023.107712_bb0085","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s10875-022-01323-4","article-title":"SLGT2 inhibitor rescues myelopoiesis in G6PC3 deficiency","volume":"42","author":"Hiwarkar","year":"2022","journal-title":"J. Clin. Immunol."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107712_bb0090","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jaip.2022.10.019","article-title":"Empagliflozin restores neutropenia and neutrophil dysfunction in a young patient with severe congenital neutropenia type 4","volume":"11","author":"Ledeczi","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.ymgme.2023.107712_bb0095","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.5114\/aoms\/150029","article-title":"The overall benefits of empagliflozin treatment in adult siblings with glycogen storage disease type Ib: one year experience","volume":"18","author":"Bidiuk","year":"2022","journal-title":"Arch. Med. Sci."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107712_bb0100","doi-asserted-by":"crossref","first-page":"207","DOI":"10.5114\/pedm.2022.116115","article-title":"Clinical characteristics and long-term outcomes of patients with glycogen storage disease type 1b: a retrospective multi-center experience in Poland","volume":"28","author":"Kaczor","year":"2022","journal-title":"Pediatr. Endocrinol. Diabetes Metab."},{"issue":"Supplement 1","key":"10.1016\/j.ymgme.2023.107712_bb0105","doi-asserted-by":"crossref","first-page":"8320","DOI":"10.1182\/blood-2022-169243","article-title":"Oral SGLT2 inhibitors in glycogen storage disease type Ib and G6PC3-deficiency. Preliminary results from an off-label study of 21 patients","volume":"140","author":"Donadieu","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2023.107712_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/jha2.649","article-title":"Finding balance between mature and immature neutrophils: The effects of empagliflozin in GSD-Ib","author":"Guerra","year":"2023","journal-title":"eJHaem"},{"issue":"3","key":"10.1016\/j.ymgme.2023.107712_bb0115","first-page":"252","article-title":"Patient-reported outcomes on empagliflozin treatment in glycogen storage disease type Ib: an international questionnaire study","volume":"64","author":"Grunert","year":"2023","journal-title":"JIMD Rep."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107712_bb0120","doi-asserted-by":"crossref","DOI":"10.1097\/PG9.0000000000000356","article-title":"Clinical remission of severe Crohn\u2019s disease with empagliflozin monotherapy in a pediatric patient with glycogen storage disease type 1b","volume":"4","author":"Collen","year":"2023","journal-title":"JPGN Rep."},{"issue":"9","key":"10.1016\/j.ymgme.2023.107712_bb0125","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00018-023-04884-8","article-title":"SGLT5 is the renal transporter for 1,5-anhydroglucitol, a major player in two rare forms of neutropenia","volume":"80","author":"Diederich","year":"2023","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107712_bb0130","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2337\/diab.40.1.52","article-title":"Comparison of 1,5-anhydroglucitol, HbA1c, and fructosamine for detection of diabetes mellitus","volume":"40","author":"Yamanouchi","year":"1991","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.ymgme.2023.107712_bb0135","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4093\/dmj.2015.39.2.164","article-title":"1,5-anhydroglucitol as a useful marker for assessing short-term glycemic excursions in type 1 diabetes","volume":"39","author":"Seok","year":"2015","journal-title":"Diabetes Metab. J."},{"key":"10.1016\/j.ymgme.2023.107712_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108233","article-title":"Review of methods for detecting glycemic disorders","volume":"165","author":"Bergman","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107712_bb0145","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14737159.8.1.9","article-title":"1,5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions","volume":"8","author":"Dungan","year":"2008","journal-title":"Expert. Rev. Mol. Diagn."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107712_bb0150","first-page":"309","article-title":"Untargeted metabolomic profiling in a patient with glycogen storage disease Ib receiving empagliflozin treatment","volume":"63","author":"Tallis","year":"2022","journal-title":"JIMD Rep."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107712_bb0155","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13023-020-1343-7","article-title":"Dried blood spot versus venous blood sampling for phenylalanine and tyrosine","volume":"15","author":"van Vliet","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107712_bb0160","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13023-023-02623-7","article-title":"Glucosylsphingosine (Lyso-Gb1) as a reliable biomarker in Gaucher disease: a narrative review","volume":"18","author":"Giuffrida","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107712_bb0165","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/clinchem\/46.1.126","article-title":"Recoveries of phenylalanine from two sets of dried-blood-spot reference materials: prediction from hematocrit, spot volume, and paper matrix","volume":"46","author":"Adam","year":"2000","journal-title":"Clin. Chem."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107712_bb0170","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13052-021-01100-w","article-title":"Crohn disease-like enterocolitis remission after empagliflozin treatment in a child with glycogen storage disease type Ib: a case report","volume":"47","author":"Rossi","year":"2021","journal-title":"Ital. J. Pediatr."},{"issue":"7","key":"10.1016\/j.ymgme.2023.107712_bb0175","article-title":"Repurposing of Empagliflozin as a possible treatment for neutropenia and inflammatory bowel disease in glycogen storage disease type Ib: a case report","volume":"14","author":"Makrilakis","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.ymgme.2023.107712_bb0180","doi-asserted-by":"crossref","first-page":"1071464","DOI":"10.3389\/fped.2022.1071464","article-title":"Favorable outcome of empagliflozin treatment in two pediatric glycogen storage disease type 1b patients","volume":"10","author":"Hexner-Erlichman","year":"2022","journal-title":"Front. Pediatr."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107712_bb0190","doi-asserted-by":"crossref","first-page":"141","DOI":"10.11613\/BM.2015.015","article-title":"Understanding bland Altman analysis","volume":"25","author":"Giavarina","year":"2015","journal-title":"Biochem. Med. (Zagreb)"},{"key":"10.1016\/j.ymgme.2023.107712_bb0195","article-title":"Liver transplantation in glycogen storage disease type Ib: the role of SGLT2 inhibitors","volume":"35","author":"Murko","year":"2023","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107712_bb0200","first-page":"70","article-title":"Monitoring phenylalanine concentrations in the follow-up of phenylketonuria patients: an inventory of pre-analytical and analytical variation","volume":"58","author":"Coene","year":"2021","journal-title":"JIMD Rep."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107712_bb0205","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/dom.12064","article-title":"Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus","volume":"15","author":"Chen","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ymgme.2023.107712_bb0210","doi-asserted-by":"crossref","first-page":"1145111","DOI":"10.3389\/fendo.2023.1145111","article-title":"Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders","volume":"14","author":"Maiorana","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"22","key":"10.1016\/j.ymgme.2023.107712_bb0215","first-page":"3641","article-title":"Correlation between 1,5-anhydroglucitol and glycemic excursions in type 2 diabetic patients","volume":"124","author":"Sun","year":"2011","journal-title":"Chin. Med. J."},{"issue":"12","key":"10.1016\/j.ymgme.2023.107712_bb0220","article-title":"New insights into the use of empagliflozin-A","volume":"10","author":"Forycka","year":"2022","journal-title":"Comprehensive Rev. Biomed."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107712_bb0225","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/ng.3809","article-title":"Whole-genome sequencing identifies common-to-rare variants associated with human blood metabolites","volume":"49","author":"Long","year":"2017","journal-title":"Nat. Genet."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719223003426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719223003426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T17:15:12Z","timestamp":1735233312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719223003426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1096719223003426"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2023.107712","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DBS are suitable for 1,5-anhydroglucitol monitoring in GSD1b and G6PC3-deficient patients taking SGLT2 inhibitors to treat neutropenia","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2023.107712","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107712"}}